What type of drug is Lorbrena?
Medically reviewed by Drugs.com. Last updated on Dec 1, 2020.
What condition is it used to treat?
Lorbrena is an anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI).
Lorbrena (lorlatinib) was approved in November 2018 for the treatment of patients with ALK-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on other ALK TKIs.
Lorbrena is a new option for NSCLC patients who have progressed but provides an option to remain on oral therapy. The recommended dosage is 100 mg orally once daily.
Other ALK tyrosine kinase inhibitors include:
Related Medical Questions
- What is the difference between Opdivo and Keytruda?
- Pembrolizumab vs. nivolumab: how do they compare?
- What is the cost of Tecentriq?
- How effective is Alecensa for ALK-positive NSCLC?
- How long do you take Alecensa for?
- How does Alecensa work?
- What is the difference between Mvasi and Avastin?
- What is Tagrisso used for?
- What type of cancer is Tecentriq used to treat?
- What type of drug is Libtayo?
- What type of lung cancer is Vizimpro used to treat?
- What is Alecensa used to treat?
- What type of drug is Alunbrig?